ATE453669T1 - Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen - Google Patents

Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen

Info

Publication number
ATE453669T1
ATE453669T1 AT03726739T AT03726739T ATE453669T1 AT E453669 T1 ATE453669 T1 AT E453669T1 AT 03726739 T AT03726739 T AT 03726739T AT 03726739 T AT03726739 T AT 03726739T AT E453669 T1 ATE453669 T1 AT E453669T1
Authority
AT
Austria
Prior art keywords
fused
protein
ferritin
applications
polymeric
Prior art date
Application number
AT03726739T
Other languages
English (en)
Inventor
Daniel Carter
Chester Li
Original Assignee
New Century Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New Century Pharmaceuticals filed Critical New Century Pharmaceuticals
Application granted granted Critical
Publication of ATE453669T1 publication Critical patent/ATE453669T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/805—Haemoglobins; Myoglobins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03726739T 2002-05-10 2003-05-12 Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen ATE453669T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37914502P 2002-05-10 2002-05-10
PCT/US2003/014617 WO2003094849A2 (en) 2002-05-10 2003-05-12 Ferritin fusion proteins for use in vaccines and other applications

Publications (1)

Publication Number Publication Date
ATE453669T1 true ATE453669T1 (de) 2010-01-15

Family

ID=29420496

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03726739T ATE453669T1 (de) 2002-05-10 2003-05-12 Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen

Country Status (8)

Country Link
US (2) US7097841B2 (de)
EP (1) EP1504037B1 (de)
CN (2) CN1659187A (de)
AT (1) ATE453669T1 (de)
AU (1) AU2003228962A1 (de)
CA (1) CA2485363C (de)
DE (1) DE60330767D1 (de)
WO (1) WO2003094849A2 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220100A1 (en) * 2000-07-21 2004-11-04 Essentia Biosystems, Inc. Multi-component biological transport systems
US9089521B2 (en) * 2001-11-01 2015-07-28 Robert H. Broyles Method for regulating production of hemoglobin beta chains
US7998704B2 (en) * 2002-03-07 2011-08-16 Carnegie Mellon University Methods for magnetic resonance imaging
IL163937A0 (en) 2002-03-07 2005-12-18 Univ Carnegie Mellon Contrast agents for magnetic resonance imaging andmethods realted thereto
ATE453669T1 (de) * 2002-05-10 2010-01-15 New Century Pharmaceuticals Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen
FI20030615A0 (fi) * 2003-04-24 2003-04-24 Marko Virta Nanopartikkeli bioaffiniteettimäärityksiin
EP1608977B1 (de) * 2003-04-02 2007-08-15 Turun Yliopisto Nanopartikel für bioaffinitätstests
US7888064B2 (en) * 2004-12-02 2011-02-15 Csir Gram positive bacterial cells comprising a disrupted flagellin gene, flagellin-based fusion proteins and use in removal of metal ions from a liquid
CN101501062B (zh) * 2005-07-26 2012-07-18 康哲医药研究(深圳)有限公司 新型生物活性肽及其新用途
IL286053B2 (en) * 2005-10-18 2023-03-01 Nat Jewish Health A process for making red blood cells using immortal hematopoietic stem cells and erythropoietin
KR100772491B1 (ko) 2005-10-31 2007-11-01 고려대학교 산학협력단 ＤｎａＫ와 고친화력을 가지는 모티브를 포함하는 주형단백질과 탐침 단백질이 융합된 단백질 나노입자
GB0621894D0 (en) * 2006-11-02 2006-12-13 Iti Scotland Ltd Magnetic recognition system
AU2007329171A1 (en) * 2006-12-04 2008-06-12 Innovative Purification Technologies Pty Ltd Protein particles
US20080311145A1 (en) * 2007-04-04 2008-12-18 Specigen, Inc. Protein cage immunotherapeutics
US8986702B2 (en) 2008-05-16 2015-03-24 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
EP2318435B1 (de) 2008-08-28 2015-12-23 Taiga Biotechnologies, Inc. Myc-modulatoren, verfahren zu ihrer verwendung und verfahren zur identifikation von mitteln zur myc-modulierung
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
CN102115746B (zh) * 2009-12-30 2013-06-05 中国科学院地质与地球物理研究所 一种单分散性磁性人铁蛋白的制备方法
US9241986B2 (en) 2010-01-04 2016-01-26 Kj Biosciences Llc DPS fusion proteins for use in vaccines and diagnostics
AU2011311946B8 (en) 2010-10-06 2014-10-09 University Of Washington Through Its Center For Commercialization Polypeptides and their use in treating and limiting respiratory syncytial virus infection
US9441019B2 (en) 2011-09-23 2016-09-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Influenza hemagglutinin protein-based vaccines
EP2762488B1 (de) * 2011-09-30 2018-11-21 Korea University Research and Business Foundation, Sejong Campus Peptid zur synthese von kieselsäure und verwendung davon
KR101477123B1 (ko) * 2011-10-12 2014-12-29 한국생명공학연구원 항체결합 펩타이드-페리틴 융합단백질 및 이의 용도
EP2834263B9 (de) 2012-04-05 2019-02-27 University Of Washington Through Its Center For Commercialization Epitope-scaffold immunogenische peptide gegen rsv
WO2013173256A2 (en) 2012-05-16 2013-11-21 Kj Biosciences, Llc New and improved influenza vaccines
CA3133302A1 (en) 2012-07-20 2014-01-23 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment comprising a myc polypeptide
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
EP3906939A1 (de) * 2013-10-11 2021-11-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr-virus-impfstoffe
KR101612095B1 (ko) * 2014-01-16 2016-04-26 한국과학기술연구원 바이오마커의 조기 검출 및 정밀 정량화가 가능한 바이오마커 탐지용 프로브 및 이의 용도
ES2924721T3 (es) 2014-05-27 2022-10-10 Us Health Trímeros de la región del tallo de la hemaglutinina estabilizada de la influenza y usos de los mismos
WO2016048246A1 (en) * 2014-09-25 2016-03-31 Nanyang Technological University Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages
EP3240567A2 (de) 2014-12-31 2017-11-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Neuartige multivalente impfstoffe auf nanopartikelbasis
CN105801706B (zh) * 2014-12-31 2019-10-22 深圳先进技术研究院 蝎氯毒素多肽-铁蛋白重链融合蛋白、自组装蛋白质纳米笼及其制备方法和应用
US10420830B2 (en) 2015-01-29 2019-09-24 Agency For Science, Technology And Research Nanocapsules carrying chikungunya-associated peptides
PL412787A1 (pl) * 2015-06-22 2017-01-02 Magdalena Król Oparty na makrofagach celowany system dostarczania związków związanych z ferrytyną
US10781238B2 (en) * 2015-09-02 2020-09-22 Kyungpook National University Industry-Academic Cooperation Foundation Human-derived ferritin monomer fragment and fusion polypeptide using same
US10688175B2 (en) 2015-10-13 2020-06-23 Daniel C. Carter NSP10 self-assembling fusion proteins for vaccines, therapeutics, diagnostics and other nanomaterial applications
KR20180088458A (ko) * 2015-12-04 2018-08-03 다나-파버 캔서 인스티튜트 인크. 암의 치료를 위한 mica/b 알파 3 도메인의 백신접종
CN107344969B (zh) * 2016-05-05 2021-03-05 中国科学院武汉病毒研究所 一种纳米流感疫苗及构建方法和应用
EP3474893A1 (de) 2016-06-27 2019-05-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Selbstorganisierende insektenferritin-nanopartikel zur darstellung von co-assemblierten trimeren antigenen
CN106046177B (zh) * 2016-08-19 2020-02-21 北华大学 P-5m-Fc融合蛋白及其表达基因、制备方法和应用
KR20240042570A (ko) 2016-09-02 2024-04-02 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 안정화된 그룹 2 인플루엔자 헤마글루티닌 줄기 영역 삼량체 및 그의 용도
AU2017367730A1 (en) 2016-12-02 2019-06-06 Taiga Biotechnologies, Inc. Nanoparticle formulations
US11261236B2 (en) 2017-01-06 2022-03-01 Kyungpook National University Industry-Academic Cooperation Foundation Fusion peptide comprising thrombus-targeting peptide, ferritin fragment and thrombolytic peptide, and use thereof
US10538756B2 (en) 2017-03-06 2020-01-21 The Trustees Of Princeton University Disordered protein-based seeds for molecular clustering
CN108976299B (zh) * 2017-06-05 2020-02-14 昆山新蕴达生物科技有限公司 一种改善抗体片段亲和力和体内半衰期的方法
CN107325176B (zh) * 2017-06-16 2020-12-25 神威药业集团有限公司 源于血红蛋白的免疫活性人胎盘多肽
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
EP3773698A1 (de) 2018-04-03 2021-02-17 Sanofi Ferritinproteine
JP2021519599A (ja) * 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ 抗原性ｏｓｐａポリペプチド
WO2019236736A1 (en) * 2018-06-05 2019-12-12 International Aids Vaccine Initiative Ferritin nanoparticle displaying an hiv trimer
US11883485B2 (en) 2018-08-29 2024-01-30 Fred Hutchinson Cancer Center Methods of eliciting antibodies that bind to full-length glycosylated HIV-1 Env using multimerized Env cores
CN109966483B (zh) * 2019-04-08 2021-07-30 中国科学院过程工程研究所 一种基于铁蛋白的多抗原通用流感疫苗及其制备方法和应用
KR20210149121A (ko) * 2019-04-25 2021-12-08 애그리컬쳐럴 테크놀로지 리서치 인스티튜트 돼지열병 바이러스 감염 예방용 재조합 단백질 및 이를 포함하는 조성물과 세포
TWI776048B (zh) * 2019-04-25 2022-09-01 財團法人農業科技研究院 預防豬瘟病毒感染之重組蛋白質及含其之組合物及細胞
WO2020243895A1 (zh) * 2019-06-04 2020-12-10 上海鑫湾生物科技有限公司 促进毛发生长和/或再生的疫苗、其制备方法及其应用
CN110478480B (zh) * 2019-08-22 2022-06-24 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 基于铁蛋白纳米颗粒的羊口疮f1l疫苗及其制备方法
CN110898219B (zh) * 2019-12-11 2022-01-14 中国科学院生物物理研究所 基于铁蛋白与preS1抗原基因融合表达的疫苗
CN111603555B (zh) * 2020-03-23 2022-10-21 东北农业大学 一种自组装牛副流感病毒3型纳米颗粒样抗原及其应用
WO2021231729A1 (en) 2020-05-13 2021-11-18 Sanofi Adjuvanted stabilized stem hemagglutinin nanoparticles and methods of using the same to induce broadly neutralizing antibodies against influenza
CN112342207B (zh) * 2020-11-27 2022-09-30 华侨大学 一种低速离心纯化重组木聚糖酶的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571697A (en) * 1989-05-05 1996-11-05 Baylor College Of Medicine Texas Medical Center Expression of processed recombinant lactoferrin and lactoferrin polypeptide fragments from a fusion product in Aspergillus
ATE99656T1 (de) 1989-08-18 1994-01-15 Monsanto Co Ferritinanaloge.
US5248589A (en) 1991-02-21 1993-09-28 Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Separation of cells and biological macromolecules by ferritin conjugates
CA2258082A1 (en) * 1996-06-12 1997-12-18 Yajun Guo Cellular vaccines and immunotherapeutics and methods for their preparation
ATE453669T1 (de) * 2002-05-10 2010-01-15 New Century Pharmaceuticals Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen

Also Published As

Publication number Publication date
US20040006001A1 (en) 2004-01-08
EP1504037B1 (de) 2009-12-30
DE60330767D1 (de) 2010-02-11
CN105566497A (zh) 2016-05-11
CA2485363A1 (en) 2003-11-20
AU2003228962A8 (en) 2003-11-11
US20060251679A1 (en) 2006-11-09
WO2003094849A2 (en) 2003-11-20
AU2003228962A1 (en) 2003-11-11
CN1659187A (zh) 2005-08-24
US7608268B2 (en) 2009-10-27
EP1504037A2 (de) 2005-02-09
US7097841B2 (en) 2006-08-29
EP1504037A4 (de) 2005-06-08
WO2003094849A3 (en) 2004-04-15
CA2485363C (en) 2014-10-28

Similar Documents

Publication Publication Date Title
ATE453669T1 (de) Ferritinfusionsproteine zur verwendung für impfstoffe und andere anwendungen
DE60127933D1 (de) Chimäre proteine und anwendungen
EA200700391A1 (ru) Комбинированное лечение с применением слитых белков трансферрина, содержащих glp-1
GEP20105111B (en) Rage fusion proteins and methods of use
EE200200538A (et) Rekombinantsete verehüübimisfaktorite produtseerimine inimese rakuliinides
DE60325892D1 (de) Stellungs- und verwendungsverfahren
DK1767546T3 (da) Angiogenese-inhiberende kimært protein og dets anvendelse
DE60125751D1 (de) Zusammensetzungen und verfahren zur behinderung der vervielfältigung von hiv-1
MX2020010466A (es) Vectores de virus que evitan anticuerpos.
EA201070623A1 (ru) Конструкция из полипептидов однодоменных антител, применение композиции, ее содержащей, и способ лечения ревматоидного артрита
HRP20041108B1 (hr) Peptidi povezani sa tumorom koji se vežu na mhc molekule
MX2011006846A (es) Virus de fiebre porcina clasico recombinante (csfv) comprendiendo una proteina e2 modificada y metodos para generar dicho csfv.
DE60208343D1 (de) FUSIONSPROTEINE aus hirudin und proinsulin oder insulin
MX2009011638A (es) Composiciones basadas en gp5 de prrsv y metodos.
CY1111431T1 (el) Μεταλλαγμενες πρωτεϊνες πλακουντιου αυξητικου παραγοντα τυπου 1, μεθοδος παρασκευης και εφαρμογες αυτων
UA91820C2 (ru) Терапевтическое применение вариантов хемокинов
HUP0303534A2 (hu) Csökkent immunogenitású módosított interferon-béta
MXPA05008704A (es) Proteinas de fusion de muteinas de interferon alfa con propiedades mejoradas.
DE60335726D1 (de) Chromoprotein und fluoroproteine
MX2021014649A (es) Dominio de repetición de anquirina diseñado con estabilidad mejorada.
FR2857267B1 (fr) Formulation stabilisante et solubilisante pour les proteines cryoprecipitables.
HUP0303309A2 (hu) Csökkentett immunogenitású módosított interferon-alfa
EA200501711A1 (ru) Семейство секретируемых белков
DE602004007924D1 (de) Thrombopoietinproteine mit verbesserten eigenschaften
DK1578772T3 (da) Cytokiner og cytokinreceptorer med reduceret immunogenicitet

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties